The FDA has approved a new presentation of Alvotech and Teva’s SELARSDI, for the treatment of ulcerative colitis and Crohn's ...

In an exclusive interview, the CEO of ImmunoPrecise Antibodies described the benefits of rabbit monoclonal antibodies in ...

Otsuka has reported positive interim results from its Phase III trial evaluating sibeprenlimab, a treatment for adults with ...

Global Cancer Antibody Drug Conjugates Market Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, Oct. 23, 2024 ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathyAdditional oral presentation ...

A new research paper was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition." ...

Image Credit: Nemes Laszlo/Shutterstock.com Contact stirring, however, demonstrates just one type of stress that can occur ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Explore how mAbs are transforming disease treatment, the evolution from murine to humanized antibodies, and the impact of biosimilar antibodies on cost-effective therapies.

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

The initial program, dubbed Geneious Luma, aims to focus on monoclonal and multispecific antibodies. It will take the ability ...